Report cover image

Global Radiopharmaceutical Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 16, 2025
Length 193 Pages
SKU # APRC20280618

Description

Summary

According to APO Research, the global Radiopharmaceutical market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Radiopharmaceutical is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Radiopharmaceutical is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Radiopharmaceutical market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Radiopharmaceutical is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Radiopharmaceutical market include China Isotope & Radiation, Novartis, Dongcheng, Bayer, SIEMENS, Mundipharma, Lantheus, Jubilant Pharma and GE Healthcare, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Radiopharmaceutical, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Radiopharmaceutical, also provides the sales of main regions and countries. Of the upcoming market potential for Radiopharmaceutical, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Radiopharmaceutical sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Radiopharmaceutical market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Radiopharmaceutical sales, projected growth trends, production technology, application and end-user industry.

Radiopharmaceutical Segment by Company

China Isotope & Radiation
Novartis
Dongcheng
Bayer
SIEMENS
Mundipharma
Lantheus
Jubilant Pharma
GE Healthcare
Eli Lilly
Curium Pharma
Cardinal Health
Bracco Imaging
Aurobindo Pharma
Radiopharmaceutical Segment by Type

Diagnostic Radiopharmaceuticals
Therapeutic Radiopharmaceuticals
Radiopharmaceutical Segment by Application

Oncology
Cardiology
Other
Radiopharmaceutical Segment by Region

North America

United States
Canada
Europe

Germany
France
U.K.
Italy
Netherlands
Asia-Pacific

China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America

Mexico
Brazil
Argentina
Middle East & Africa

Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Radiopharmaceutical status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Radiopharmaceutical market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Radiopharmaceutical significant trends, drivers, influence factors in global and regions.
6. To analyze Radiopharmaceutical competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceutical market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceutical and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceutical.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Radiopharmaceutical market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Radiopharmaceutical industry.
Chapter 3: Detailed analysis of Radiopharmaceutical manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Radiopharmaceutical in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Radiopharmaceutical in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

193 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Radiopharmaceutical Sales Value (2020-2031)
1.2.2 Global Radiopharmaceutical Sales Volume (2020-2031)
1.2.3 Global Radiopharmaceutical Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Radiopharmaceutical Market Dynamics
2.1 Radiopharmaceutical Industry Trends
2.2 Radiopharmaceutical Industry Drivers
2.3 Radiopharmaceutical Industry Opportunities and Challenges
2.4 Radiopharmaceutical Industry Restraints
3 Radiopharmaceutical Market by Company
3.1 Global Radiopharmaceutical Company Revenue Ranking in 2024
3.2 Global Radiopharmaceutical Revenue by Company (2020-2025)
3.3 Global Radiopharmaceutical Sales Volume by Company (2020-2025)
3.4 Global Radiopharmaceutical Average Price by Company (2020-2025)
3.5 Global Radiopharmaceutical Company Ranking (2023-2025)
3.6 Global Radiopharmaceutical Company Manufacturing Base and Headquarters
3.7 Global Radiopharmaceutical Company Product Type and Application
3.8 Global Radiopharmaceutical Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Radiopharmaceutical Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Radiopharmaceutical Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Radiopharmaceutical Market by Type
4.1 Radiopharmaceutical Type Introduction
4.1.1 Diagnostic Radiopharmaceuticals
4.1.2 Therapeutic Radiopharmaceuticals
4.2 Global Radiopharmaceutical Sales Volume by Type
4.2.1 Global Radiopharmaceutical Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Radiopharmaceutical Sales Volume by Type (2020-2031)
4.2.3 Global Radiopharmaceutical Sales Volume Share by Type (2020-2031)
4.3 Global Radiopharmaceutical Sales Value by Type
4.3.1 Global Radiopharmaceutical Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Radiopharmaceutical Sales Value by Type (2020-2031)
4.3.3 Global Radiopharmaceutical Sales Value Share by Type (2020-2031)
5 Radiopharmaceutical Market by Application
5.1 Radiopharmaceutical Application Introduction
5.1.1 Oncology
5.1.2 Cardiology
5.1.3 Other
5.2 Global Radiopharmaceutical Sales Volume by Application
5.2.1 Global Radiopharmaceutical Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Radiopharmaceutical Sales Volume by Application (2020-2031)
5.2.3 Global Radiopharmaceutical Sales Volume Share by Application (2020-2031)
5.3 Global Radiopharmaceutical Sales Value by Application
5.3.1 Global Radiopharmaceutical Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Radiopharmaceutical Sales Value by Application (2020-2031)
5.3.3 Global Radiopharmaceutical Sales Value Share by Application (2020-2031)
6 Radiopharmaceutical Regional Sales and Value Analysis
6.1 Global Radiopharmaceutical Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Radiopharmaceutical Sales by Region (2020-2031)
6.2.1 Global Radiopharmaceutical Sales by Region: 2020-2025
6.2.2 Global Radiopharmaceutical Sales by Region (2026-2031)
6.3 Global Radiopharmaceutical Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Radiopharmaceutical Sales Value by Region (2020-2031)
6.4.1 Global Radiopharmaceutical Sales Value by Region: 2020-2025
6.4.2 Global Radiopharmaceutical Sales Value by Region (2026-2031)
6.5 Global Radiopharmaceutical Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Radiopharmaceutical Sales Value (2020-2031)
6.6.2 North America Radiopharmaceutical Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Radiopharmaceutical Sales Value (2020-2031)
6.7.2 Europe Radiopharmaceutical Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Radiopharmaceutical Sales Value (2020-2031)
6.8.2 Asia-Pacific Radiopharmaceutical Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Radiopharmaceutical Sales Value (2020-2031)
6.9.2 South America Radiopharmaceutical Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Radiopharmaceutical Sales Value (2020-2031)
6.10.2 Middle East & Africa Radiopharmaceutical Sales Value Share by Country, 2024 VS 2031
7 Radiopharmaceutical Country-level Sales and Value Analysis
7.1 Global Radiopharmaceutical Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Radiopharmaceutical Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Radiopharmaceutical Sales by Country (2020-2031)
7.3.1 Global Radiopharmaceutical Sales by Country (2020-2025)
7.3.2 Global Radiopharmaceutical Sales by Country (2026-2031)
7.4 Global Radiopharmaceutical Sales Value by Country (2020-2031)
7.4.1 Global Radiopharmaceutical Sales Value by Country (2020-2025)
7.4.2 Global Radiopharmaceutical Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.5.2 USA Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.6.2 Canada Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.8.2 Germany Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.9.2 France Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.9.3 France Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.11.2 Italy Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.12.2 Spain Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.13.2 Russia Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.16.2 China Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.16.3 China Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.17.2 Japan Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.19.2 India Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.19.3 India Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.20.2 Australia Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.24.2 Chile Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.26.2 Peru Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.28.2 Israel Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.29.2 UAE Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.31.2 Iran Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Radiopharmaceutical Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Radiopharmaceutical Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Radiopharmaceutical Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 China Isotope & Radiation
8.1.1 China Isotope & Radiation Comapny Information
8.1.2 China Isotope & Radiation Business Overview
8.1.3 China Isotope & Radiation Radiopharmaceutical Sales, Value and Gross Margin (2020-2025)
8.1.4 China Isotope & Radiation Radiopharmaceutical Product Portfolio
8.1.5 China Isotope & Radiation Recent Developments
8.2 Novartis
8.2.1 Novartis Comapny Information
8.2.2 Novartis Business Overview
8.2.3 Novartis Radiopharmaceutical Sales, Value and Gross Margin (2020-2025)
8.2.4 Novartis Radiopharmaceutical Product Portfolio
8.2.5 Novartis Recent Developments
8.3 Dongcheng
8.3.1 Dongcheng Comapny Information
8.3.2 Dongcheng Business Overview
8.3.3 Dongcheng Radiopharmaceutical Sales, Value and Gross Margin (2020-2025)
8.3.4 Dongcheng Radiopharmaceutical Product Portfolio
8.3.5 Dongcheng Recent Developments
8.4 Bayer
8.4.1 Bayer Comapny Information
8.4.2 Bayer Business Overview
8.4.3 Bayer Radiopharmaceutical Sales, Value and Gross Margin (2020-2025)
8.4.4 Bayer Radiopharmaceutical Product Portfolio
8.4.5 Bayer Recent Developments
8.5 SIEMENS
8.5.1 SIEMENS Comapny Information
8.5.2 SIEMENS Business Overview
8.5.3 SIEMENS Radiopharmaceutical Sales, Value and Gross Margin (2020-2025)
8.5.4 SIEMENS Radiopharmaceutical Product Portfolio
8.5.5 SIEMENS Recent Developments
8.6 Mundipharma
8.6.1 Mundipharma Comapny Information
8.6.2 Mundipharma Business Overview
8.6.3 Mundipharma Radiopharmaceutical Sales, Value and Gross Margin (2020-2025)
8.6.4 Mundipharma Radiopharmaceutical Product Portfolio
8.6.5 Mundipharma Recent Developments
8.7 Lantheus
8.7.1 Lantheus Comapny Information
8.7.2 Lantheus Business Overview
8.7.3 Lantheus Radiopharmaceutical Sales, Value and Gross Margin (2020-2025)
8.7.4 Lantheus Radiopharmaceutical Product Portfolio
8.7.5 Lantheus Recent Developments
8.8 Jubilant Pharma
8.8.1 Jubilant Pharma Comapny Information
8.8.2 Jubilant Pharma Business Overview
8.8.3 Jubilant Pharma Radiopharmaceutical Sales, Value and Gross Margin (2020-2025)
8.8.4 Jubilant Pharma Radiopharmaceutical Product Portfolio
8.8.5 Jubilant Pharma Recent Developments
8.9 GE Healthcare
8.9.1 GE Healthcare Comapny Information
8.9.2 GE Healthcare Business Overview
8.9.3 GE Healthcare Radiopharmaceutical Sales, Value and Gross Margin (2020-2025)
8.9.4 GE Healthcare Radiopharmaceutical Product Portfolio
8.9.5 GE Healthcare Recent Developments
8.10 Eli Lilly
8.10.1 Eli Lilly Comapny Information
8.10.2 Eli Lilly Business Overview
8.10.3 Eli Lilly Radiopharmaceutical Sales, Value and Gross Margin (2020-2025)
8.10.4 Eli Lilly Radiopharmaceutical Product Portfolio
8.10.5 Eli Lilly Recent Developments
8.11 Curium Pharma
8.11.1 Curium Pharma Comapny Information
8.11.2 Curium Pharma Business Overview
8.11.3 Curium Pharma Radiopharmaceutical Sales, Value and Gross Margin (2020-2025)
8.11.4 Curium Pharma Radiopharmaceutical Product Portfolio
8.11.5 Curium Pharma Recent Developments
8.12 Cardinal Health
8.12.1 Cardinal Health Comapny Information
8.12.2 Cardinal Health Business Overview
8.12.3 Cardinal Health Radiopharmaceutical Sales, Value and Gross Margin (2020-2025)
8.12.4 Cardinal Health Radiopharmaceutical Product Portfolio
8.12.5 Cardinal Health Recent Developments
8.13 Bracco Imaging
8.13.1 Bracco Imaging Comapny Information
8.13.2 Bracco Imaging Business Overview
8.13.3 Bracco Imaging Radiopharmaceutical Sales, Value and Gross Margin (2020-2025)
8.13.4 Bracco Imaging Radiopharmaceutical Product Portfolio
8.13.5 Bracco Imaging Recent Developments
8.14 Aurobindo Pharma
8.14.1 Aurobindo Pharma Comapny Information
8.14.2 Aurobindo Pharma Business Overview
8.14.3 Aurobindo Pharma Radiopharmaceutical Sales, Value and Gross Margin (2020-2025)
8.14.4 Aurobindo Pharma Radiopharmaceutical Product Portfolio
8.14.5 Aurobindo Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Radiopharmaceutical Value Chain Analysis
9.1.1 Radiopharmaceutical Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Radiopharmaceutical Sales Mode & Process
9.2 Radiopharmaceutical Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Radiopharmaceutical Distributors
9.2.3 Radiopharmaceutical Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.